
A disease we thought was gone is roaring back—here's why
New CDC data reported on Wednesday reveals that the country tallied its highest number of measles cases since 1992. As of July 8, the U.S. has reported 1,288 cases of measles across 39 states. Of those documented measles cases, almost 90% are concentrated in outbreaks of three or more cases.
The 2025 case tally halfway through the year already exceeds the post-1992 record of 1,274 measles cases reported in 2019. While the official measles numbers are alarming as is, any published number is likely an undercount due to the likelihood of unreported cases.
A wildly contagious virus that poses a particular risk to children, measles was once considered a disease of the past in the U.S. due to widespread uptake of a safe, effective vaccine. The CDC declared measles officially eliminated in the U.S. in 2000, a milestone the agency's website still hails as a historic achievement attributable to a 'highly effective vaccination program' in the country.
Of the 1,288 reported measles cases this year, 29% were children under age 5 and two-thirds of the reported measles infections were people under the age of 19. Of those infected, 92% were either unvaccinated or had an unknown vaccination status, while 8% had received at least one dose of the measles, mumps, and rubella vaccine. Of the total cases, 13% resulted in hospitalization and three measles deaths have been reported so far.
Clusters of measles outbreaks
While cases have been documented across most states, a major measles outbreak in Texas sent case counts soaring this year. By early July, Texas had reported 753 measles cases, mostly concentrated in a Mennonite community in Gaines County, near the border with New Mexico. Gaines County is one of the least-vaccinated areas of Texas, with almost 14% of school-aged children skipping at least one vaccine dose during the last school year.
Beyond major outbreaks like the one in Texas, measles is making inroads in places that haven't reported cases in years. North Dakota recorded its first case in more than a decade in May, when the spread of measles was limited to 11 states.
When it gains a foothold in unvaccinated communities, measles infections spread like wildfire. The virus is extraordinarily contagious and can survive in the air hours after an infected person sneezes or coughs. An estimated 9 out of 10 non-immune people exposed to the measles virus go on to become infected – a rate that outstrips COVID-19, the flu and even the deadly Ebola virus.
While vaccines are required for students in all 50 states, the majority of states let students opt out for personal or religious reasons, including Texas. Around the country, more parents of school-aged children are taking that out and declining vaccines in recent years. From 2019 to 2023, measles vaccination rates fell from 95% to 92%. That 95% threshold is important: A community is considered protected against the measles virus when 95% of its members are vaccinated. In Texas, kindergarten vaccination rates are now under 95% in half of counties around the state.
National vaccination rates aren't declining in a vacuum. Vaccine skepticism – once a fringe belief in the U.S. – has become supercharged in recent years, with a proliferation of misinformation powering its rise. Political leaders have seized on worries about vaccine safety to sow political divisions and in some cases to cash in on the millions flowing to anti-vaccine causes.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
DermaRite recalls antiseptic soaps and topical lotion due to infection risk
A U.S. company that makes health care products is recalling four over-the-counter skin cleansers and an anti-itch lotion it says could lead to "serious and life-threatening infections." New Jersey-based DermaRite Industries announced on Friday that it was voluntarily recalling the health care products due to the fact that they may cause a microbial contamination known as Burkholderia cepecia, which may result in adverse reactions, particularly in immunocompromised individuals. In a company statement, DermaRite said the contaminated products "may be used by immunosuppressed individuals or by people who are attending to these individuals." The recall notice was also shared by the U.S. Food and Drug Administration. Symptoms for Burkholderia Cepecia Complex can range from fever and fatigue to serious respiratory infections, according to the Centers for Disease Control and Prevention. "In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis," the company said in its notice. According to its website, DermaRite creates wound care products, cleansers, moisturizers, hand soaps and other items for patients and caregivers operating in health care settings. DermaRite said it has not received any reports of adverse events related to this recall. Reached for comment, the company referred CBS MoneyWatch back to its statement. The items included in the recall include DermaKleen, DermaSarra, KleenFoam and PeriGiene — all of which serve slightly different health care purposes. DermaKleen, for example, is a antimicrobial hand cleanser, while DermaSarra offers relief from poison ivy, insect bites, and other skin irritants. DermaRite said it has reached out to its distributors and customers by e-mail and advised them "to immediately examine available inventory and destroy all affected products in accordance with each facility's process." The company said consumers who have used the products should contact their physician or health care provider if they have experienced any issues possibly related to use of the products. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Trump says he's placing D.C. police under federal control, deploying National Guard Jamie Lee Curtis: The 60 Minutes Interview Solve the daily Crossword
Yahoo
16 minutes ago
- Yahoo
Proposed deal would bring former Prospect exec back to distressed hospitals
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Nor Healthcare Systems Corp. appears poised to buy Prospect Medical Holding's California hospital portfolio out of bankruptcy, according to documents filed to a Texas bankruptcy court last week. The company was named the stalking horse bidder for the California assets, meaning Nor will set a floor price for the hospitals should an auction occur. Nor Healthcare was registered in Nevada just three months ago. The company lists no board of directors, general partners or trustees in its initial business application. However, it does name a director: Prospect veteran Michael Sarian. Sarian served as SVP of Prospect's hospital operations between 2005 and 2012. It could be a competitive auction. California is Prospect's core market, and attorneys told the court this month they have 'multiple active bidders' for the facilites. Should an auction go forward, an outcome will be decided by the end of the month, with a final sales hearing scheduled for Aug. 28. Dive Insight: Debt-ridden Prospect has sought to sell multiple facilities and opted to close others since filing for bankruptcy in January following years of financial difficulties. Each time, Prospect told the court it needed to act fast to divest in the face of mounting liquidity pressures. Critics say Prospect's to blame for its own cash problems and lack of interested buyers. Lawmakers in Pennsylvania and Connecticut say the health system ran its facilities into the ground by prioritizing profits over investments in patient care. California hospitals were meant to be safe from a fire sale. Prospect CEO Von Crockett entered the restructuring process intent on keeping the California market intact. However, six hospitals are now up for grabs, including Bellflower Behavioral Health Hospital, Los Angeles Community Hospital, Norwalk Community Hospital, Southern California Hospital at Culver City, Southern California Hospital at Hollywood and Van Nuys Behavioral Health Hospital. Prospect did not respond to requests for comment about possible sale terms for its California portfolio, including a purchase price. If Nor emerges as the buyer, it will be a homecoming of sorts for Sarian. Prospect purchased its first four California hospitals from Alta Hospitals System in 2007. Sarian sat at the head, serving as CEO of Alta and SVP of hospital operations for Prospect for approximately seven years, according to his LinkedIn profile and securities filings. Sarian's tenure coincides with the beginning of private equity firm Leonard Green & Partner's ownership of Prospect, which spanned 2010 to 2021. A bipartisan Senate investigation released earlier this year found that as early as 2010 Prospect began siphoning millions of dollars toward dividends and fees to benefit Leonard Green & Partners while hospital quality declined. After leaving Prospect in 2012, Sarian served as president of hospital operations at Prime Healthcare, managing operations for 45 hospitals across 15 states, before launching hospital turnaround firm Healthcare Systems of America and affiliate American Healthcare Systems. There, Sarian built a portfolio mostly by buying hospitals out of bankruptcy, including North Carolina-based Randolph Health in 2021 and eight hospitals formerly run by Steward Health Care last year. But American Healthcare Systems has had financial struggles of its own, according to a report from the Wall Street Journal. The health system has reportedly fallen behind on vendor payments at some of its facilities and, in other cases, failed to pay doctors on time. At one hospital, payment delays caused vendors to stop shipping critical medical supplies, including dialysis products, according to the report. Both Prime and HSA, where Sarian has worked, have done business with Prospect's long-time landlord, real estate investment trust Medical Properties Trust. Some familiarity could be a plus for helping Nor broker the California deal, because the stalking horse bid agreement stipulates that whomever takes over Prospect's California hospitals will enter into lease agreement with MPT. Such leases are often contentious. Lawmakers and academics have argued that sale leaseback transactions between hospitals and real estate investment trusts benefit investors by giving them quick access to cash but ultimately harm health systems by saddling them with unaffordable rent payments. HSA, Prospect, MPT and Nor did not respond to requests for comment on this article. Recommended Reading Prospect Medical Systems lays off 125 Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Heartflow's IPO raises $364M
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Heartflow's initial public offering grossed $364.2 million after the volume and price of the shares sold exceeded the original expectations. The company listed last week and completed the sale of the overallotment on Monday, adding almost $50 million through the sale of additional shares. Heartflow's stock rose in its first two days on public markets, closing at almost $30 on Monday. The company priced its IPO at $19 a share. Dive Insight: Heartflow has developed software for making 3D heart models from coronary computed tomography angiography scans. In a clinical trial, the company linked its lead product, Heartflow FFRCT Analysis, to a 78% improvement in identifying patients in need of revascularization. Heartflow was aiming to sell 12.5 million shares for between $15 and $17 each when it set its IPO range early this month. At the midpoint of the range, the company would have raised $200 million before fees under the original plan. By the time Heartflow finalized the terms last week, the company had agreed to sell 16.7 million shares for $19 each. The changes increased the initial gross IPO amount to $316.7 million. Heartflow raised a further $47.5 million when underwriters took up their options to buy an additional 2.5 million shares in the overallotment. The company estimates net proceeds after fees will be $333.2 million. Heartflow's first two days on public markets provided further evidence of investor enthusiasm. The stock closed at $28.75 on Friday. After peaking and troughing during Monday's session, Heartflow closed up at just below $30. The closing price on Monday was almost 58% higher than the IPO price. The offering extends a recent uptick in IPO activity. Caris Life Sciences priced its IPO at $21 in June, having originally set a range of $16 to $18, and the precision medicine company's stock closed above $30 on Monday. Carlsmed hit the middle of its expected $14 to $16 range, raising more than $100 million to advance its spine platform, but its share price had slipped to $13 by market close on Monday. Recommended Reading Heartflow prices IPO, aiming to net about $180M